Cingulate Inc. (CING)
Largest Insider Buys in Sector
CING Stock Price History Chart
CING Stock Performance
About Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Insider Activity of Cingulate Inc.
Over the last 12 months, insiders at Cingulate Inc. have bought $0 and sold $841 worth of Cingulate Inc. stock.
On average, over the past 5 years, insiders at Cingulate Inc. have bought $687,630 and sold $11,525 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $3,349 was made by Callahan Jennifer L. (Corporate Controller) on 2023‑09‑15.
List of Insider Buy and Sell Transactions, Cingulate Inc.
| 2024-08-15 | Sale | EVP and COO | 202 0.0346% | $4.17 | $841 | 0.00% | ||
| 2023-09-15 | Corporate Controller | 5,000 0.031% | $0.67 | $3,349 | -91.95% | |||
| 2023-08-11 | director | 1.82M 16.1208% | $0.55 | $1M | -88.68% | |||
| 2023-05-15 | Corporate Controller | 2,000 0.0184% | $1.01 | $2,020 | -61.39% | |||
| 2023-05-12 | Corporate Controller | 4,000 0.0374% | $1.08 | $4,320 | -62.62% | |||
| 2022-12-16 | Chief Executive Officer | 10,000 0.0879% | $1.02 | $10,166 | -11.54% | |||
| 2022-12-14 | Corporate Controller | 7,548 0.0728% | $0.99 | $7,468 | +0.16% | |||
| 2022-12-14 | Chief Executive Officer | 13,267 0.1305% | $1.01 | $13,400 | +0.16% | |||
| 2022-12-13 | director | 28,934 0.2505% | $0.98 | $28,422 | -9.36% | |||
| 2022-12-13 | Chief Executive Officer | 1,733 0.0154% | $1.01 | $1,750 | -9.36% | |||
| 2022-11-29 | Corporate Controller | 1,530 0.0144% | $0.98 | $1,499 | +0.64% | |||
| 2022-11-28 | Corporate Controller | 3,487 0.0304% | $0.98 | $3,417 | -7.00% | |||
| 2022-11-23 | EVP and COO | 1,111 0.0098% | $0.90 | $1,000 | +2.74% | |||
| 2022-11-23 | EVP, GC and Secretary | 3,575 0.0295% | $0.84 | $3,003 | +2.74% | |||
| 2022-11-22 | director | 85,000 0.766% | $0.88 | $74,851 | +6.90% | |||
| 2022-09-08 | Corporate Controller | 3,500 0.0312% | $1.50 | $5,250 | -33.89% | |||
| 2022-09-06 | 74,500 0.6459% | $1.52 | $113,225 | -36.13% | ||||
| 2022-09-01 | EVP and COO | 636 0.0057% | $1.57 | $999 | -36.13% | |||
| 2022-06-01 | EVP and COO | 200 0.0018% | $1.18 | $236 | -6.90% | |||
| 2022-05-17 | EVP and COO | 200 0.0017% | $1.21 | $242 | -12.19% |
Insider Historical Profitability
| Myers Laurie | EVP and COO | 0 0% | $4.86 | 5 | 1 | |
| Werth Peter J. | director | 2798320 87.1145% | $4.86 | 4 | 0 | <0.0001% |
| GIVENS GREGG WM | director | 154318 4.8041% | $4.86 | 2 | 0 | |
| Callahan Jennifer L. | Corporate Controller | 45508 1.4167% | $4.86 | 8 | 0 | <0.0001% |
| Schaffer Shane J. | Chief Executive Officer | 41500 1.2919% | $4.86 | 3 | 0 |